Assembly Biosciences announces preclinical data, to present at EASL Congress

Assembly Biosciences (ASMB) announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver, EASL, Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands. The late-breaker poster presentation titled “Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D” highlights preclinical data supporting the advancement of ABI-6250 into an ongoing Phase 1a clinical study. Results demonstrate that in cell culture, ABI-6250 specifically inhibits both HDV and hepatitis B virus at low nanomolar levels and shows selectivity versus a panel of other viruses. ABI-6250 showed minimal effects on cell viability in vitro across multiple cell types, and also selectively inhibited the sodium taurocholate cotransporting polypeptide bile acid transporter compared to a broad range of other transporters in vitro. The poster presentation titled “Sustained inhibition of HBV replication and HBsAg levels after long-term treatment with CAM ABI-4334 in human hepatocytes” describes in vitro studies of ABI-4334 evaluating multiple viral biomarkers of HBV infection. These results showed durable reduction in HBV nucleic acids and antigens in human hepatocytes following a one-month course of treatment with ABI-4334.